Predominant SARS-CoV-2 variant impacts accuracy when screening for infection using exhaled breath vapor

BACKGROUND: New technologies with novel and ambitious approaches are being developed to diagnose or screen for SARS-CoV-2, including breath tests. The US FDA approved the first breath test for COVID-19 under emergency use authorization in April 2022. Most breath-based assays measure volatile metabol...

Descripción completa

Detalles Bibliográficos
Autores principales: McCartney, Mitchell M., Borras, Eva, Rojas, Dante E., Hicks, Tristan L., Hamera, Katherine L., Tran, Nam K., Tham, Tina, Juarez, Maya M., Lopez, Enrique, Kenyon, Nicholas J., Davis, Cristina E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731983/
https://www.ncbi.nlm.nih.gov/pubmed/36482179
http://dx.doi.org/10.1038/s43856-022-00221-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731983/
https://www.ncbi.nlm.nih.gov/pubmed/36482179
http://dx.doi.org/10.1038/s43856-022-00221-5

Ejemplares similares